BIOLOGICAL STUDY aiming at describing clinicophatological features of EO-CRC vs SO-CRC
BIOLOGICAL STUDY aiming at describing clinicophatological features of EO-CRC vs SO-CRC: Description of clinicophatological features of EO-CRC vs SO-CRC
Study summary
Observational, retrospective and prospective multicentric Italian study of patients diagnosed with colorectal cancer between age 18-40, aiming at underpinning the biology of vEO-CRC, including colibactin as well as a broader proteo-genomic characterization, to identify potential new therapeutic targets specifically directed to this peculiar subset of patients.
Eligibility
Sex
ALL
Min age
18 Years
Max age
40 Years
Healthy volunteers
No
1. Patients with diagnosis of colorectal cancer (vEO-CRC: 18-40 years of age), or SO-CRC diagnosed later than age 60;
2. Informed consent signature from alivepatient;
3. Availability of formalin-fixed paraffin embedded (FFPE) tumor samples (5 FFPE 4uM thick slides and 10 FFPE 10 uM thick slides) and/or fresh tumor tissue retrieved from a biopsy or surgical procedure performed as per clinical standard of care.
Primary outcome measure(s)
clinicopathological features description — Apr 2024- Dec2026 Primaryto analyze clinicopathological features of a cohort of sporadic vEO-CRC (n=300), compared to an equal cohort of standard-onset (SO-CRC) patients diagnosed at 60 years or later;
overall survival and response to standard-of-care treatments analisys — Apr 2024- Dec2026 to analyze overall survival and response to standard-of-care treatments of a cohort of sporadic vEO-CRC (n=300), compared to an equal cohort of standard-onset (SO-CRC) patients diagnosed at 60 years or later;
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
